Verisante Technology Inc. is a Canadian medical device company committed to commercializing innovative systems for the early detection of cancer. The company’s exclusive platform technology allows it to develop and offer a range of compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers.
The company currently has two products on the market. The first product is the Verisante Aura which is a novel multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer. The second product is the Verisante Core which uses the same basic technology for the early detection of other cancers including lung, colon and cervical.
Verisante Technology announced yesterday that its stock had begun trading on the OTC market’s highest tier for international stocks, OTCQX International. Investors can find current financial disclosure and real-time Level 2 quotes for the company on www.otcqx.com or www.otcmarkets.com. Verisante’s principal American liaison on OTCQX is Hodgson Russ LLP.
The move to the OTCQX will give the company more visibility and its shareholders superior information on Verisante. The reason behind the move for the company is to build investor confidence and its shareholder base in the United States.
For more information on Verisante Technology, please visit its website at www.verisante.com